Q-omics provides the consensus-scored PCDHA7 profile across patient tissues and cancer cell-line models. PCDHA7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PCDHA7 is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, PCDHA7 RNA expression shows 11,814 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRP, and TGCT as cancer lineages where PCDHA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHA7 survival associations across molecular data types. PCDHA7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHA7 RNA expression–survival associations across cancer types. High PCDHA7 expression shows unfavorable associations in LUSC, STAD and DLBC, but favorable associations in UVM, OV and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PCDHA7 RNA expression.
This table summarizes PCDHA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for PCDHA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHA7 shows lower tumor expression in KICH and READ and higher tumor expression in KIRP, THCA, LIHC and LUAD. The KIRP box plot shows higher PCDHA7 RNA expression in tumor versus normal tissue (log2 FC = +0.600, t-test p = .017).
This table shows molecular features associated with PCDHA7 in patient tissues and cancer cell lines. In patient samples, PCDHA7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
